Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Boyd MUDENDA"'
Autor:
Engelbert BILASHOBOKA, Boyd MUDENDA, Nosiku MUNYINDA, Fabiola VINCENT MOSHI, Dominic M. KAMBARAGE
Publikováno v:
Food and Environment Safety, Vol 17, Iss 4, Pp 404-412 (2018)
Worldwide, antimicrobials are widely used in food producing animals for treatment and/or prophylaxis of diseases. In Tanzania, irrational administration of antimicrobials, notably oxytetracycline (OTC) is common because of the under-developed animal
Externí odkaz:
https://doaj.org/article/7d3e0bcde8814c019eb3e95f8248af9d
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 11, Iss 10, p e0005946 (2017)
The current rabies control strategy in Zambia is based on dog vaccination, dog population control and dog movement restrictions. In Nyimba district of Zambia, dog vaccination coverage is low but the incidence of dog bites is high which places the com
Externí odkaz:
https://doaj.org/article/ed289c135a5744ebaf768bf239846450
Publikováno v:
Journal of Diabetes Research, Vol 2016 (2016)
Background. The control of diabetes mellitus depends on several factors that also include individual lifestyles. We assessed glycaemic control status and self-management behaviours that may influence glycaemic control among diabetic outpatients. Meth
Externí odkaz:
https://doaj.org/article/0cb0b269e6ba4ca6a0a766e94bb531d8
Publikováno v:
The Pan African Medical Journal, Vol 19, Iss 354 (2014)
INTRODUCTION: the glycaemic control status of diabetic patients affects the management of their disorder. We examined the glycaemic control and clinical factors that may influence the achievement of the glycaemic control targets among diabetic out-pa
Externí odkaz:
https://doaj.org/article/15fb521b025140fcbd493eb6ec24d5ce
Autor:
Matthew S. Davids, Asher Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kriachok, Hanna Usenko, Vladimir Ivanov, Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk, Alexander Myasnikov, Zvenyslava Maslyak, Andrew Proidakov, Olga Uspenskaya, Elena Borisenkova, Paula Marlton, Tanya Siddiqi, Allison Winter, Tamila Lysa, Bulat Bakirov, Lei Fu, Zi Chen, Min Yu, Mingyu Li, Laura Glass, Mohammad Ahmad, Olena Karpenko, Iurii Osipov, Asit De, Ben Paudyal, Hengbang Wang, Robert Winkler, Nashat Gabrail, Vinod Ganju, Tatiana S. Konstantinova, Olga S. Samoylova, Dajun Yang, Yifan Zhai
Publikováno v:
Blood. 140:2326-2328
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43fec5f75e1286dfcef8a36c5c7cbaa6
https://doi.org/10.1182/blood-2022-160386
https://doi.org/10.1182/blood-2022-160386
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients.Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d3221b48c4ae9f44d5518d04b2e195
https://doi.org/10.1158/1078-0432.c.6526244.v1
https://doi.org/10.1158/1078-0432.c.6526244.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Immunohistology expression of Trop-2 vs response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c28d7d0d017206cdcb8eeb9b98c5f6
https://doi.org/10.1158/1078-0432.22466114
https://doi.org/10.1158/1078-0432.22466114
Autor:
David M. Goldenberg, Robert M. Sharkey, William A. Wegener, Boyd Mudenda, Pius P. Maliakal, Serengulam V. Govindan, Wells A. Messersmith, Ronald Scheff, Kevin Kalinsky, Leena Gandhi, Tirrell Johnson, Allyson Ocean, Bryan J. Schneider, Charles J. Schneider, Jamal Misleh, Michael J. Guarino, W. Thomas Purcell, Gregory A. Masters, Ebenezer A. Kio, D. Ross Camidge, Alexander N. Starodub, Rebecca S. Heist, Jhanelle E. Gray
Evaluation of IHC staining vs best overall response in SCLC treated with 8 or 10 mg/kg starting dose of sacituzumab govitecan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b47b04cd98cbbe62d66c192352ea6bce
https://doi.org/10.1158/1078-0432.22466111
https://doi.org/10.1158/1078-0432.22466111
Autor:
Carrie Smith, Olga Samoylova, V. E. Ivanov, Bo Huang, Allison M. Winter, Hanna Usenko, Andrew Proidakov, Tetiana Perekhrestenko, Tamila Lysa, Olena Karpenko, Matthew S. Davids, Alan P Skarbnik, Yifan Zhai, Elena Borisenkova, Nashat Y. Gabrail, Boyd Mudenda, Asher Chanan-Khan, Olena Kyselova, Zi Chen, Tatiana Konstantinova, Tanya Siddiqi, Mohammad Ahmad, Tetiana Popovska, Mingyu Li, Iryna Kriachok, Dajun Yang, Olga S. Uspenskaya, Halyna Pylypenko, John M. Pagel, Bulat Bakirov, Les Lukavetsky
Publikováno v:
Blood. 138:1554-1554
Background: BCL-2 inhibition with venetoclax has proved to be highly effective treatment for patients with CLL. However, when administered to patients with CLL who have a high tumor burden, venetoclax is associated with an elevated risk of tumor lysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d5c0b5c03ac533322a6b0fff45e3ee9
https://doi.org/10.1182/blood-2021-152811
https://doi.org/10.1182/blood-2021-152811
Autor:
Allyson J. Ocean, David M. Goldenberg, Pius Maliakal, Michael J. Guarino, William A. Wegener, Kevin Kalinsky, Alexander Starodub, D. Ross Camidge, Jamal Misleh, Wells A. Messersmith, Boyd Mudenda, Robert M. Sharkey, Jhanelle E. Gray, Ebenezer A. Kio, Leena Gandhi, Tirrell Johnson, Gregory A. Masters, Bryan J. Schneider, Rebecca S. Heist, Charles J. Schneider, Ronald J. Scheff, W. Thomas Purcell, Serengulam V. Govindan
Publikováno v:
Clinical Cancer Research. 23:5711-5719
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients. Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e3588f6c198004cae5f52ab2059f6c0
https://doi.org/10.1158/1078-0432.ccr-17-0933
https://doi.org/10.1158/1078-0432.ccr-17-0933